Chemotherapy-induced Peripheral Neuropathy Clinical Trial
Official title:
Transauricular Vagus Nerve Stimulation in the Treatment of Chemotherapy-induced Peripheral Neuropathy: A Randomized Controlled Study
Verified date | June 2022 |
Source | Peking University People's Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Chemotherapy induced peripheral neuropathy is common in tumor patients receiving chemotherapy. Nowaday, CIPN is mainly treated with drugs, but the therapeutic effect is not satisfactory. Previous studies have found that inflammatory immune mechanism plays an important role in neuropathic pain. Vagus nerve stimulation can not only relieve pain by regulating the autonomic nervous system, but also participate in the immune response. Investigators hope that the treatment by vagus nerve electrical stimulation through ear skin can improve the pain and neurotoxicity scores of CIPN patient.If it is proved that vagus nerve stimulation can effectively treat CIPN, it will become a simple and safe non-drug treatment which has good application prospects.
Status | Enrolling by invitation |
Enrollment | 26 |
Est. completion date | November 1, 2022 |
Est. primary completion date | August 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Patient is currently receiving chemotherapy drugs with neurotoxicity 2. New or worsening numbness and / or pain in the hands and / or feet, and no other cause explains the above symptoms Exclusion Criteria: 1. Patients with sinus bradycardia, long QT syndrome, sick sinus syndrome or other arrhythmias, mental diseases, cardiac pacemakers or other electrical stimulation devices after implantation. 2. Patients taking analgesics due to pain in other parts of the body. |
Country | Name | City | State |
---|---|---|---|
China | People's Hospital of Peking University | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Peking University People's Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | NRS(numerical rating scale) | 0-10,0 =no pain, 10 = the most severe pain. | Day0 | |
Primary | NRS(numerical rating scale) | 0-10,0 =no pain, 10 = the most severe pain. | Day3 | |
Primary | NRS(numerical rating scale) | 0-10,0 =no pain, 10 = the most severe pain. | Day5 | |
Primary | NRS(numerical rating scale) | 0-10,0 =no pain, 10 = the most severe pain. | Day8 | |
Primary | NRS(numerical rating scale) | 0-10,0 =no pain, 10 = the most severe pain. | Day14 | |
Primary | NRS(numerical rating scale) | 0-10,0 =no pain, 10 = the most severe pain. | Day30 | |
Primary | NRS(numerical rating scale) | 0-10,0 =no pain, 10 = the most severe pain. | Day60 | |
Primary | NRS(numerical rating scale) | 0-10,0 =no pain, 10 = the most severe pain. | Day90 | |
Secondary | NCI-CTC v4.0 neurotoxicity classification | Assess the degree of motor neurotoxicity and sensory neurotoxicity | Day1,Day3,Day5,Day8,Day14,Day30,Day60,Day90 | |
Secondary | QST( Quantitative Sensory Testing) | left finger, thermal thretshold,thermal pain threshold,cold threshold,cold pain threshold, | Day1,Day14 | |
Secondary | IL-2,IL-4,IL-6,IL-10,IFN-?,TNF-a | Hematological examination to test the concentration of IL-2,IL-4,IL-6,IL-10,IFN-?,TNF-a | Day1,Day14 | |
Secondary | Athens insomnia scale | <4 No sleep disorder,4-6=Suspicious insomnia,>6=Insomnia | Day1,Day8,Day14,Day30,Day60,Day90 | |
Secondary | SF-12,Short From health survey -12 | Calculate the Physical Component Summary (PCS) and
Mental Component Summary (MCS).The higher the score, the worse the quality of life |
Day1,Day8,Day14,Day30,Day60,Day90 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05528263 -
Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial)
|
N/A | |
Completed |
NCT03272919 -
Chemotherapy Induced Peripheral Neuropathy (CIPN)
|
N/A | |
Not yet recruiting |
NCT06430814 -
Clinical Biomarker of Paclitaxel-induced Peripheral Neuropathy
|
||
Not yet recruiting |
NCT05840562 -
Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy
|
Phase 3 | |
Completed |
NCT02553863 -
The Effectiveness and Cost-effectiveness of Acupuncture in Managing Chemotherapy-induced Peripheral Neuropathy
|
N/A | |
Recruiting |
NCT04786977 -
Physiologic Measure of VIPN
|
||
Completed |
NCT03655587 -
Impact of an Orthotic Intervention in Children With Peripheral Neuropathy
|
N/A | |
Completed |
NCT03687970 -
A New Method for Identifying Sensory Changes in Painful Chemotherapy-induced Peripheral Neuropathy (CIPN)
|
N/A | |
Terminated |
NCT04770402 -
Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients
|
N/A | |
Completed |
NCT03254394 -
Lidocaine for Oxaliplatin-induced Neuropathy
|
Phase 1/Phase 2 | |
Completed |
NCT04367480 -
Effects of Transcutaneous Electrical Nerve Stimulation on Chemotherapy-Induced Peripheral Neuropathy
|
N/A | |
Recruiting |
NCT04237194 -
A New Diagnostic Method to Assess Paclitaxel-Induced Peripheral Neuropathy
|
||
Completed |
NCT04843410 -
Effect of Exercise in the Management of Peripheral Neuropathy
|
N/A | |
Terminated |
NCT03782402 -
Cannabinoids for Taxane Induced Peripheral Neuropathy
|
Phase 2 | |
Not yet recruiting |
NCT06389721 -
Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy
|
||
Recruiting |
NCT05121558 -
The Effect of Yoga on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)
|
Phase 3 | |
Withdrawn |
NCT04492436 -
A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo
|
Phase 2 | |
Not yet recruiting |
NCT03112057 -
Visualize Nociceptor Changes in Neuropathic Human
|
N/A | |
Completed |
NCT04262778 -
Diagnostic of Chemotherapy Induced Neuropathy in Children
|
||
Recruiting |
NCT06324344 -
Transcutaneous Electrical Nerve Stimulation (TENS) for Chemotherapy Induced Peripheral Neuropathy (CIPN)
|
N/A |